DOACs Should Be Standard of Care in Cancer-Associated Thrombosis DOACs Should Be Standard of Care in Cancer-Associated Thrombosis
Direct oral anticoagulants are more effective than dalteparin in reducing the risk of thrombosis recurrence without significantly increasing the risk of major bleeding.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Blood clots: Four skin changes in the arms and legs that are warning signs
DEEP vein thrombosis is a type of blood clot that develops in the legs or arms. The "dangerous" condition might require a prompt call to 999, so be aware of the warning signs. (Source: Daily Express - Health)
Source: Daily Express - Health - January 19, 2022 Category: Consumer Health News Source Type: news
Incoming NHS England chair Richard Meddings admits he has used private healthcare
Former banker Richard Medding, 63 - who is Sajid Javid's pick to chair the NHS - revealed he chose to use private health care 'late last year' when being treated for deep vein thrombosis. (Source: the Mail online | Health)
Source: the Mail online | Health - January 18, 2022 Category: Consumer Health News Source Type: news
Direct oral anticoagulants significantly decrease recurrent venous thrombosis for adult cancer patients, Mayo Clinic study finds
ROCHESTER, Minn. — Direct oral anticoagulants should be considered the standard of care to treat adult patients with cancer-associated thrombosis, according to a new, ongoing study by Mayo Clinic researchers. Thrombosis is a condition where blood clots form in blood vessels of the legs. These clots can travel to t he lungs and become lodged in blood vessels, causing a pulmonary embolism. Thrombotic outcomes increase mortality in cancer patients and are the second most common cause of… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - January 18, 2022 Category: Research Source Type: news
Shorter Course of Anticoagulant Therapy Adequate for Provoked VTE in Children Shorter Course of Anticoagulant Therapy Adequate for Provoked VTE in Children
For children with acute provoked venous thromboembolism, 6 weeks of anticoagulant therapy is as effective as a three-month course of anticoagulant therapy, results of a new clinical trial suggest.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 13, 2022 Category: Intensive Care Tags: Critical Care News Source Type: news
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
THURSDAY, Dec. 30, 2021 -- For patients at high risk for venous thromboembolism (VTE) discharged after COVID-19 hospitalization, thromboprophylaxis with rivaroxaban is associated with improved clinical outcomes, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization
A randomized, open-label trial showed improved clinical outcomes from a low dose of direct oral anticoagulant in patients at high risk for venous thromboembolism and low risk for bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 17, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Prevention and management of venous thromboembolism in COVID-19, Scottish Intercollegiate Guidelines Network
Guideline provides recommendations based on current evidence for best practice in pharmacological prophylaxis& management of thrombotic complications of all degrees of severity of COVID-19, including advice for non-pregnant adults in ICU and non-ICU settings and in the community. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 17, 2021 Category: Consumer Health News Source Type: news
U.S. Government Recommends Americans Get the Pfizer-BioNTech or Moderna COVID-19 Shots Instead of J & J ’s
Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health advisers recommended Thursday.
The strange clotting problem has caused nine confirmed deaths after J&J vaccinations — while the Pfizer and Moderna vaccines don’t come with that risk and also appear more effective, advisers to the Centers for Disease Control and Prevention said.
It’s an unusual move and the CDC’s director, Dr. Rochelle Walensky, must decide whether to accept the panel’s advice.
Until now the U.S. has treated all thr...
Source: TIME: Health - December 17, 2021 Category: Consumer Health News Authors: LAURAN NEERGAARD and MIKE STOBBE / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
Johnson & Johnson Statement on its COVID-19 Vaccine Following CDC ACIP Meeting
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson & Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson & Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi], ...
Source: Johnson and Johnson - December 16, 2021 Category: Pharmaceuticals Source Type: news
CDC Panel Backs mRNA COVID Vaccines Over J & J Due to Clot Risk CDC Panel Backs mRNA COVID Vaccines Over J & J Due to Clot Risk
The panel cited the rare but potentially fatal cases of thrombosis with thrombocytopenia syndrome that can arise after the J&J vaccine.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2021 Category: Cancer & Oncology Tags: Infectious Diseases News Source Type: news
CDC Panel Backs mRNA COVID Vaccines Over J & J Due to Clot Risk
The CDC panel voted unanimously to prefer the Pfizer and Moderna vaccines after hearing a safety update on cases of thrombosis with thrombocytopenia syndrome, a condition that causes large clots that deplete the blood of platelets, resulting in uncontrolled bleeding. (Source: WebMD Health)
Source: WebMD Health - December 16, 2021 Category: Consumer Health News Source Type: news
Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC
NEW BRUNSWICK, N.J., December 16, 2021 - Remarks made by Penny Heaton, Global R&D Head of Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson:Good afternoon. My name is Penny Heaton, and I am the Global R&D Head for Vaccines at Janssen.Let me state at the outset that based on data, we are confident in the positive benefit-risk profile of our vaccine. It is saving lives here in the US today and on every continent around the globe. Our vaccine is different. It is long-lasting, it offers high levels of protection, and it provides breadth of protection. Our vaccine has flexible dosing, is easy to store ...
Source: Johnson and Johnson - December 16, 2021 Category: Pharmaceuticals Source Type: news
FDA Updates TTS Risks, Cautions for Janssen COVID-19 Vaccine FDA Updates TTS Risks, Cautions for Janssen COVID-19 Vaccine
The vaccine ' s updated fact sheets include a contraindication for a subgroup of potential recipients as well as mortality figures for people who develop thrombosis with thrombocytopenia syndrome.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
